Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Fungal Infection Reports
Erschienen in: Current Fungal Infection Reports 3/2017

08.07.2017 | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Fungal Paronychia. Clinical, Diagnosis and Treatment Aspects

verfasst von: Martin Arce, Daniela Gutiérrez-Mendoza

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this study is to recognize and expand the knowledge of mycotic paronychia as a variable clinical condition due to various predisposing factors and multiple fungal organisms.

Recent Findings

Candida-associated mycotic paronychia is common but other non-dermatophyte molds, such as Fusarium, are identified as potential agents of paronychia and onychomycosis.

Summary

Mycotic paronychia is characterized by inflammation of the proximal or lateral nail folds caused by certain fungi. Mycological analysis is necessary to identify the causal agent and prescribe an appropriate treatment. Further studies are needed to know the involved microorganisms in the disease and the pathogenicity factors involved in this localized area of the nail apparatus.
Literatur
1.
2.
3.
Daniel CR III, Lorizzo M, Piraccini BM, Tosti A. Grading simple chronic paronychia and onycholysis. Int J Dermatol. 2006a;45(12):1447–8.CrossRefPubMed
4.
5.
Daniel CR 3rd, Daniel MP, Daniel CM, et al. Chronic paronychia and onycholysis: a thirteen-year experience. Cutis. 1996;58(6):397–401.PubMed
6.
Lorizzo M, Piraccini BM, Tosti A. Chronic paronychia: different causes and their treatment. Expert Rev Dermatol. 2006;3(1):375–8.
7.
8.
Hay RJ, Baran R, Moore MK, Wilkinson JD. Candida onychomycosis—an evaluation of the role of Candida species in nail disease. Br J Dermatol. 1988;118(1):47–58.CrossRefPubMed
9.
Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011;65:1219–27.CrossRefPubMed
10.
Simonetti O, Bernardini ML, Arzeni D, et al. Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years. Mycopathologia. 2004;158:271–4.CrossRefPubMed
11.
12.
Rigopoulos D, Larios G, Gregoriu S. Acute and chronic paronychia. Am Fam Physician. 2008;77(3):339–48.PubMed
13.
Elewsky BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415–29.
14.
Torres-Guerrero E, Arenas R. Onychomycosis: an illustrated guide to diagnosis and treatment. In: Tosti A, Vlahovic TC, Arenas R, editors. Candida onychomycosis. Switzerland: Springer International Publishing; 2017.CrossRef
15.
Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171:937–58.CrossRefPubMed
16.
Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol. 2002;47(1):73–6.CrossRefPubMed
17.
18.
19.
Daniel CR III, Lorizzo M, Piraccini BM, Tosti A. Grading simple chronic paronychia and onycholysis. J Dermatol. 2006b;45:1447–8.
20.
Dorko E, Jautová J, Pilipcinec E, Tkáciková L. Occurrence of Candida strains in cases of paronychia. Folia Microbiol (Praha). 2004;49(5):591–5.CrossRef
21.
Manzano-Gayosso P, Méndez-Tovar LJ, Arenas R, et al. Levaduras causantes de onicomicosis en cuatro centros dermatológicos mexicanos y su sensibilidad antifúngica a compuestos azólicos. Rev Iberoam Micol. 2011;28(1):32–5.CrossRefPubMed
22.
Fich F, Abarzua-Araya A, Perez M, et al. Candida parapsilosisand Candida guillermondii: emerging pathogens in nail candidiasis. Indian J Dermatol. 2014;59(1):24–9.CrossRefPubMedPubMedCentral
23.
Arendrup MC. Candida and candidemia susceptibility and epidemiology. Dan Med J. 2013;60(11):1–32. B4698
24.
25.
Sardi J, Scorzoni L, Bernardi T, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62:10–24.CrossRefPubMed
26.
Jayatilake JA, Tilakaratne WM, Panagoda GJ, et al. Candidal onychomycosis: a mini-review. Mycopathologia. 2009;168(4):165–73.CrossRefPubMed
27.
Reyes Delgado K, Staines-Boone AT, Amaya Guerra M, et al. Candidiasis mucocutánea crónica. Dermatol Rev Mex. 2013;57:378–81.
28.
29.
Cano-Pallares C, Ávila-Fuentes AE, Jesús-Silva MA, et al. Piedra blanca y otras infecciones causadas por Trichosporon spp. Dermatol Rev Mex. 2016;60(6):499–507.
30.
Fermin-Goncalves D, Alemán-Mejias E, Colella MT, et al. Estudio de una serie de casos de Tricosporonosis. Dermatol Venez. 2015;53(2):41–5.
31.
Taj-Aldeen SJ, Al-Ansari N, El Shafei S, et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol. 2009;47(6):1791–9.CrossRefPubMedPubMedCentral
32.
Rizzitelli G, Guanziroli E, Moschin A, et al. Onychomycosis caused by Trichosporon mucoide. Int J Infect Dis. 2016;42:61–3.CrossRefPubMed
33.
34.
Nenoff P, Krüger C, Ginter-Hanselmayer G, Tietz HJ. Mycology—an update. Part 1: dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014b;12(3):188–209.PubMed
35.
Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–70.PubMed
36.
37.
Lagace J, Cellier E. A case report of a mixed Chaetomium globosum/Trichophyton mentagrophytes onychomycosis. Medl Mycol Case Rep. 2012;1:76–8.CrossRef
38.
Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl. 3):27–46.CrossRefPubMed
39.
Muhammed M, Anagnostou T, Desalermos A, et al. Fusarium infection report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013;92(6):305–16.CrossRefPubMedPubMedCentral
40.
• Al-Hatmi AM, Hagen F, Menken SB, et al. Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015. Emerg Microbes Infect. 2016;5(12):e124. doi:10.​1038/​emi.​2016.​126. Molecular analyses of Fusaria have revealed medically important and diversity species.CrossRefPubMedPubMedCentral
41.
Motamedi M, Ghasemi Z, Shidfar MR, Hosseinpour L, et al. Growing incidence of non-dermatophyte onychomycosis in Tehran, Iran Jundishapur. J Microbiol. 2016;9(8):e40543. doi:10.​5812/​jjm.​40543.
42.
43.
Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494–502.CrossRefPubMed
44.
Hay RJ, Baran R. Fungal (Onychomycosis) and other infections involving the nail apparatus. In: Baran R, de Berker DAR, Holzberg M, Thomas L, editors. Baran and Dawber’s diseases of the nails and their management. UK: Wiley & Sons; 2012.
45.
Maddy AJ, Abrahams JL, Tosti A. Onychomycoses due to non-dermatophytic molds. In: Tosti A, Vlahovic TC, Arenas R, editors. Onychomycosis: an illustrated guide to diagnosis and treatment. Switzerland: Springer International Publishing; 2017.
46.
Gianni C, Cerri A, Crosti C. “Case report: unusual clinical features of fingernail infection by Fusarium oxysporum Mycoses”.1997; 40: 455–459.
47.
De la Herrán P, López Lozano H, Fierro-Arias L, Ponce Olvera RM, et al. Paroniquia micótica por Fusarium solani: reporte de caso y revisión de la literatura. Dermatología CMQ. 2012;10(2):139–42.
48.
Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol. 1997;136:424–7.CrossRefPubMed
49.
50.
Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium originating from toenail paronychia in a neutropenic patient. Cutis. 2010;85(4):191–4.PubMedPubMedCentral
51.
Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004a;209(2):104–10.CrossRefPubMed
52.
Chiheb S, El Machbouh L, Marnissi F. Paronychia-like cutaneous leishmaniasis. Dermatol Online J. 2015;21(11).
53.
54.
55.
56.
57.
Calderón L, Tirado-Sánchez A, Lázaro-León JM, et al. Frecuencia de alteraciones ungueales secundarias a la administración de taxanos en pacientes mexicanos. Dermatol Rev Mex. 2015;59:493–503.
58.
Lupu I, Voiculescu VM, Bacalbasa N, Prie BE, et al. Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. J Med Life. 2015;8(Special Issue):57–61.PubMedPubMedCentral
59.
Nenoff P, Krüger C, Schaller J. et al. Mycology—an update part 2: dermatomycoses: clinical picture and diagnostics. JDDG. 2014c;1610–0379/2014/1209. doi: 10.​1111/​ddg.​12420.
60.
Migheli Q, Balmas V, Harak H, et al. Molecular phylogenetic diversity of dermatologic and other human patogenic fusarial Isolates from hospitals in northern and central Italy. J Clin Microbiol. 2010a;48(4):1076–84.
61.
Jain S, Seingal VN. Itraconazole versus terbinafine in the management of onychomycosis: an overview. J Dermato Treat. 2003;14:30–42.CrossRef
62.
Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10–8.PubMedPubMedCentral
63.
64.
65.
Gianni C. Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. G Ital Dermatol Venereol. 2015;150(4):357–62.PubMed
66.
Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004b;209:104–10. doi:10.​1159/​000079593.CrossRefPubMed
67.
Kamalam A, Ajithadass K, Sentamilselvi G, Thambiah AS. Paronychia and black discoloration of a thumb nail caused by Curvularia lunata. Mycopathologia. 1992;118(2):83–4.CrossRefPubMed
Metadaten
Titel
Fungal Paronychia. Clinical, Diagnosis and Treatment Aspects
verfasst von
Martin Arce
Daniela Gutiérrez-Mendoza
Publikationsdatum
08.07.2017
Verlag
Springer US
Erschienen in
Current Fungal Infection Reports / Ausgabe 3/2017
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0286-5

Weitere Artikel der Ausgabe 3/2017

Current Fungal Infection Reports 3/2017 Zur Ausgabe

Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Antifungal Susceptibility Testing of Candida and Cryptococcus Species and Mechanisms of Resistance: Implications for Clinical Laboratories

Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Volatile Organic Compounds: Upcoming Role in Diagnosis of Invasive Mould Infections

Current Management of Fungal Infections (M Miceli, Section Editor)

Untargeted Antifungal Treatment Strategies for Invasive Candidiasis in Non-neutropenic Critically Ill Patients: Current Evidence and Insights

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Fungal Leukonychia and Melanonychia: a Review

Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Sporotrichosis: Update on Diagnostic Techniques

Current Management of Fungal Infections (M Miceli, Section Editor)

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise